Jeffrey S. Parkin

Array ( [id] => 20316741 [patent_doc_number] => 12455287 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Flow cytometry evaluation for unassociated non-enveloped viral particles [patent_app_type] => utility [patent_app_number] => 17/441177 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 37609 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 248 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378137 [patent_doc_number] => 11236134 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations [patent_app_type] => utility [patent_app_number] => 16/780495 [patent_app_country] => US [patent_app_date] => 2020-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 23234 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16780495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391432 [patent_doc_number] => 20200332373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => Compositions And Methods For Determining Resistance To Inhibitors Of Virus Entry Using Recombinant Virus Assays [patent_app_type] => utility [patent_app_number] => 16/780426 [patent_app_country] => US [patent_app_date] => 2020-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16780426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20076290 [patent_doc_number] => 12350325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2 [patent_app_type] => utility [patent_app_number] => 17/425944 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 4 [patent_no_of_words] => 15748 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15899101 [patent_doc_number] => 20200149069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 16/751470 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520761 [patent_doc_number] => 20220106610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS [patent_app_type] => utility [patent_app_number] => 17/425309 [patent_app_country] => US [patent_app_date] => 2020-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -91 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520761 [patent_doc_number] => 20220106610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS [patent_app_type] => utility [patent_app_number] => 17/425309 [patent_app_country] => US [patent_app_date] => 2020-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -91 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16207992 [patent_doc_number] => 20200240982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => Use of Specific Covalent Bonding for Oriented Immobilization of Recombinant Antibody Fragments [patent_app_type] => utility [patent_app_number] => 16/746119 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3034 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16746119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16298095 [patent_doc_number] => 20200283818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => METHODS AND COMPOSITIONS FOR EXPRESSION OF POLYPEPTIDES IN A CELL [patent_app_type] => utility [patent_app_number] => 16/744533 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506219 [patent_doc_number] => 20200385475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => SUBSTITUTION MONOTHERAPY TREATMENT FOR HIV-1 INFECTION EMPLOYING ANTIBODY PRO140 [patent_app_type] => utility [patent_app_number] => 16/737291 [patent_app_country] => US [patent_app_date] => 2020-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16737291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625847 [patent_doc_number] => 20220160862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => ADAPTATION OF ENTEROVIRUS TO VERO CELLS AND VACCINE FORMULATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/418974 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685869 [patent_doc_number] => 20220193161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => LYOPHILIZED VIRUS FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/417893 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748254 [patent_doc_number] => 20220226457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => METHOD FOR THE EXPANSION OF HPV IMMUNOGEN SPECIFIC T-CELLS [patent_app_type] => utility [patent_app_number] => 17/417596 [patent_app_country] => US [patent_app_date] => 2019-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670991 [patent_doc_number] => 20220184158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHODS OF INDUCING AN IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/416642 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090435 [patent_doc_number] => 20200199204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region [patent_app_type] => utility [patent_app_number] => 16/718322 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590463 [patent_doc_number] => 11739347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Adeno-associated virus (AAV) producer cell line and related methods [patent_app_type] => utility [patent_app_number] => 16/719251 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 26 [patent_no_of_words] => 18702 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711175 [patent_doc_number] => 20200102353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => HUMAN ENDOGENOUS RETROVIRAL PROTEIN [patent_app_type] => utility [patent_app_number] => 16/713930 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 304 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383868 [patent_doc_number] => 20220031720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => IMMUNOGENIC COMPOSITIONS CONTAINING N-GLYCOL YLNEURAMINIC ACID BEARING NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/296504 [patent_app_country] => US [patent_app_date] => 2019-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569942 [patent_doc_number] => 11318196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein [patent_app_type] => utility [patent_app_number] => 16/684103 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 44482 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866251 [patent_doc_number] => 20200140529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION [patent_app_type] => utility [patent_app_number] => 16/671742 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16671742 [rel_patent_id] =>[rel_patent_doc_number] =>)